Posthumous evaluation of advanced cancer environments
The PEACE (Posthumous Evaluation of Advanced Cancer Environment) Study
This study is trying to collect tissue samples from different parts of the body after patients with advanced cancer pass away to learn more about the disease and improve future treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University College, London Academic / other |
| Locations | 9 sites (Birmingham and 8 other locations) |
| Trial ID | NCT03004755 on ClinicalTrials.gov |
What this trial studies
The PEACE study aims to enhance cancer research by facilitating the donation of tissue samples from multiple tumor sites after the death of patients with advanced solid tumors. This observational study will collect comprehensive clinical data alongside the tissue samples to better understand the disease and its progression. By gathering samples from various locations within the body, the study seeks to overcome limitations of previous research that often relied on single-site samples. The findings could pave the way for more effective treatments and insights into cancer biology.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a confirmed diagnosis of any solid malignancy that has metastasized.
Not a fit: Patients with primary brain tumors without evidence of metastatic disease or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could significantly improve our understanding of advanced cancer and lead to better treatment strategies.
How similar studies have performed: While the approach of posthumous tissue donation is not widely tested, similar studies have shown promise in enhancing cancer research through comprehensive sample collection.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older * Confirmed diagnosis of any form of solid malignancy with metastatic disease (where the site of origin is known or unknown), with the exception of primary brain tumour in which there may not be evidence of metastatic disease * Oral and written informed consent from patient to enter the study and to undergo tumour harvesting after death or informed consent from a person in a qualifying relationship after the patient has died. Exclusion Criteria: * Medical or psychiatric condition that would preclude informed consent * History of intravenous drug abuse within the last 5 years * History of known high-risk infections (e.g. HIV/AIDS-positive, hepatitis B/C, tuberculosis and Creutzfeldt-Jacob disease).
Where this trial is running
Birmingham and 8 other locations
- Heart of England NHS Foundation Trust — Birmingham, United Kingdom (Recruiting)
- Cambridge University NHS Trust — Cambridge, United Kingdom (Recruiting)
- Greater Glasgow Health Board — Glasgow, United Kingdom (Recruiting)
- University Hospitals of Leicester NHS Trust — Leicester, United Kingdom (Recruiting)
- Guy's and St Thomas NHS Foundation Trust — London, United Kingdom (Recruiting)
- The Royal Marsden NHS Foundation Trust — London, United Kingdom (Recruiting)
- University College London Hospitals NHS Foundation Trust — London, United Kingdom (Recruiting)
- The Christie NHS Foundation Trust — Manchester, United Kingdom (Recruiting)
- Oxford University Hospitals NHS Trust — Oxford, United Kingdom (Not_yet_recruiting)
Study contacts
- Study coordinator: Abby Sharp
- Email: ctc.peace@ucl.ac.uk
- Phone: 02076799688
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.